The estimated concentration for this antibody is 1.0 mg/ml.
Alternate Names for HPi1 Antibody (HIC0-4F9)
human pancreatic endocrine islet cell
Stem cells offer a therapeutic promise for many diseases. In the case of diabetes, stem cells offer the promise that beta cells may be generated ex vivo for the possible transplantation and cure of Type I diabetes (Couri CE, et al.). For this to happen, stem cells will need to be isolated and expanded, they will need to be differentiated toward the beta cell lineage, and the differentiated cell progeny used for transplantation may need to be isolated from complex cell mixtures following differentiation. Appropriate markers targeting cell surface molecules on developing and mature pancreatic cells will be required for such research.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Publications for HPi1 Antibody (NBP1-18872)(2)
We have publications tested in 1 confirmed species: Human.
We have publications tested in 2 applications: FLOW, IHC-Fr.